YSB Inc (9885) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of YSB Inc HK$6.92, price HK$3.49, upside +98.6%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch YSB Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
39‑month range HK$3.05 – HK$59.25 · fair‑value band HK$4.84 – HK$8.99 · the HK$3.49 price screens below the HK$6.92 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow YSB in your weekly email
Every Wednesday you see whether YSB is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
YSB Inc. operates a digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China.
Show more
YSB Inc. operates a digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China. The company offers ClouMinihouse, a primary smart healthcare system that includes Future Lou, a series of advanced point-of-care testing and monitoring devices; Cloud consultation SaaS, a digital clinic management system; and ClouWiseDoctor, a smart AI doctors-aid system. It also provides SaaS solutions; and YSB eLearn that provides online courses for the preparation of the pharmacist qualification examinations. In addition, the company engages in the wholesale and retail of pharmaceutical and healthcare products. Further, it provides medical testing services; logistics services; and ClouDiagnos. YSB Inc. was founded in 2015 and is headquartered in Guangzhou, China.
Stock analysis
YSB Inc (9885) currently trades at HK$3.49, while our model-based Fair Value estimate is HK$6.92, implying the stock looks roughly 49.6% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$15.76 per share, and 22 of the 26 models we run sit above the HK$3.49 price.
Bear case: the Dividend Discount group reads lowest at HK$1.10, and 4 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$4.84 (bear) to HK$8.99 (bull), the price of HK$3.49 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
YSB Inc reported revenue of 21.0B CNY in FY2025 versus 10.1B CNY in FY2021, a compound +20.1%/yr. Reported net income was 153M CNY in FY2025.
Key figures
Market cap HK$3.1B (≈ $399M) · P/E ratio 18.2 · P/S ratio 0.13 · EPS (TTM) HK$0.1100 · Dividend yield 3.2% · Net margin 0.7% · Return on equity 6.3% · Return on assets (EBIT) −4.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 71% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 99%, 9885 screens cheaper than that median.
Fair Value models
Bear HK$4.84Fair Value HK$6.92Bull HK$8.99
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+17.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5.0% (2020) → 0.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 59 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside+98.6% · Top 25%
Profitability
Return on equity (TTM)6.3% · Above median
Return on assets0.6% · Below median
Net margin (TTM)0.7% · Below median
Operating margin (TTM)0.2% · Below median
Growth and dividend
Revenue growth22.4% · Top 25%
Dividend yield (TTM)3.2% · Below median
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "YSB Inc Fair Value". https://www.fairvalue-calculator.com/stock/9885
Frequently asked questions
Is YSB Inc (9885) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$6.92 versus a price of HK$3.49, about +99% upside (undervalued).
What is the fair value of 9885?
Our model-based fair value for YSB Inc is HK$6.92 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$3.49.
What is the quality score of 9885?
YSB Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for YSB Inc (9885)?
Our model-based price target is the fair value of HK$6.92 (as of Sep 27, 2026) from 26 valuation models. Cautious scenario HK$4.84, optimistic scenario HK$8.99. It is a calculation from audited fundamentals, not an analyst target.
What is the YSB Inc stock forecast for 2026?
Our models put fair value at HK$6.92, about +99% upside versus a price of HK$3.49 (undervalued). Cautious scenario HK$4.84, optimistic scenario HK$8.99. The calculation is refreshed regularly with new filings.
What is the revenue of YSB Inc (9885)?
YSB Inc reported trailing-twelve-month revenue of about 21.0B CNY (latest available figure, as of Sep 27, 2026).
Does YSB Inc pay a dividend?
YSB Inc currently shows a dividend yield of about 3.16% relative to its recent price (as of Sep 27, 2026).
What growth is priced into YSB Inc (9885)?
For today's price to be fair in a discounted-cash-flow model, YSB Inc would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +28.2 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 9885 use?
Our models discount YSB Inc at 10.4 %: a base by market capitalisation (small), damped by beta 0.52, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For YSB Inc that is less than minus 40 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has YSB Inc (9885) delivered so far?
Over the past 5 years revenue at YSB Inc grew +28.2 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of YSB Inc (9885) growing?
The median revenue growth in the sector is +2.6 % a year. That is the yardstick for the growth priced into YSB Inc (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of YSB Inc (9885)?
The free-cash-flow yield on the price is 29.92 %: that much free cash flow YSB Inc produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of YSB Inc (9885)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For YSB Inc it is HK$6.92 per share (as of Sep 27, 2026), against a price of HK$3.49. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is YSB Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 9885 trades below its calculated fair value: price HK$3.49, fair value HK$6.92, a gap of about +99% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9885?
No. The price is what the market pays today (HK$3.49); the fair value is what the company's own numbers justify (HK$6.92). For YSB Inc the two are HK$3.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is YSB Inc worth?
The market values YSB Inc at about HK$3.1B (market capitalisation, as of Sep 27, 2026). Per share that is HK$3.49; our models calculate a fair value of HK$6.92 per share.
What do the bullish and bearish scenarios say about 9885?
Our models span a range for YSB Inc: cautious scenario HK$4.84, base HK$6.92, optimistic HK$8.99 per share (as of Sep 27, 2026, price HK$3.49). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9885?
YSB Inc trades at a price-to-earnings ratio of 18.2 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$6.92 is built from several models across several years. Other multiples: P/B 1.1, P/S 0.1, EV/EBITDA 2.5.
How solid is the balance sheet of YSB Inc (9885)?
Balance-sheet figures for YSB Inc (as of Sep 27, 2026): return on equity 6.3%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 9885 from its 52-week high?
YSB Inc trades at HK$3.49, about 71% below its 52-week high of HK$11.96 and 14% above the low of HK$3.05 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$6.92 is for.
Which stocks are comparable to YSB Inc?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is YSB Inc stock attractive at the current price?
The data as of Sep 27, 2026: price HK$3.49, calculated fair value HK$6.92 (+99%), Quality Score 46/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9885 calculated?
We run YSB Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$6.92, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. YSB Inc currently trades 50 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of YSB Inc (9885)?
The closing price on Sep 30, 2026 was HK$3.49. Our model-based fair value is HK$6.92, about +99% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with YSB Inc right now?
The price is below even our cautious bear case (HK$4.84). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$4.84 to HK$8.99) leaves room in how you read the outcome.
Key figures of YSB Inc
How large is the market capitalisation of YSB Inc (9885)?
The market capitalisation of YSB Inc is HK$3.1B (≈ $399M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of YSB Inc (9885)?
The price-to-sales ratio of YSB Inc is 0.13 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of YSB Inc (9885)?
Earnings per share at YSB Inc are HK$0.1100 (price ÷ EPS = P/E 18.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of YSB Inc (9885)?
The dividend yield of YSB Inc is 3.2% (payout 100.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of YSB Inc (9885)?
The net margin of YSB Inc is 0.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of YSB Inc (9885)?
The return on equity (ROE) of YSB Inc is 6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of YSB Inc (9885)?
On an EBIT basis the return on assets of YSB Inc is −4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of YSB Inc (9885)?
The operating margin of YSB Inc is 0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at YSB Inc (9885)?
Revenue at YSB Inc is growing +22.4% versus a year earlier (3y avg +13.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at YSB Inc (9885)?
Earnings per share at YSB Inc are growing +769% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does YSB Inc (9885) carry?
The net debt of YSB Inc is 423M CNY (fiscal year 2025, ≈ 0.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch YSB Inc in the live analysis
One click puts YSB Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
